HomeAI · summaries
Storia in 3 fonti
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s camizestrant PDUFA date; and more
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
independent.co.uk
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a CDK4/6 inhibitor
- ·
AstraZeneca breast cancer pill faces review delay from regulators
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…
- ·
fiercebiotech.com
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses…
- ·
endpoints.news
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s camizestrant PDUFA date; and more